Biolight Israeli Life Sciences Investments Ltd., of Tel Aviv, said Visci, its wholly owned subsidiary, has filed an investigational new drug application with the FDA to conduct a phase I/IIa study with its subconjunctival Latanoprost controlled-release insert for the treatment of glaucoma.